Prime Medicine to Present at Cowen 43rd Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 9:50 a.m. ET in Boston, MA.
A live audio webcast of the presentation will be available under “Events & Presentations” in the News & Events section of the Company’s website at A replay of the webcast will be available on the Prime Medicine website for 30 days following the presentation.
About Prime Medicine
Prime Medicine is a biotechnology company committed to delivering a new class of differentiated, one-time, curative genetic therapies to address the widest spectrum of diseases. The company is deploying Prime Editing technology, a versatile, precise, efficient and broad gene editing technology, which is designed to make only the right edit at the right position within a gene. With the potential to repair approximately 90 percent of known disease-causing genetic mutations across many organs and cell types, medicines based on Prime Editing could offer a one-time curative genetic therapeutic option to a broad set of patients.
Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
Media Contact
Dan Budwick, 1AB
